Biomarin Pharmaceutical INC

BioMarin Pharmaceutical Inc. has filed an amendment to its Form 8-K to include financial statements and pro forma information related to its acquisition of Amicus Therapeutics, Inc.

BioMarin Pharmaceutical stockholders approved the 2026 director elections, auditor ratification, executive compensation, and an increase in equity incentive plan shares.

BioMarin Pharmaceutical Inc. announced first quarter 2026 financial results, reporting $766 million in total revenues and increasing its full-year revenue guidance to $3.825 billion - $3.925 billion.

BioMarin Pharmaceutical Inc. has finalized its acquisition of Amicus Therapeutics for approximately $4.8 billion, significantly expanding its rare disease drug portfolio.

BioMarin Pharmaceutical Inc. announced that it has received French FDI clearance for its merger with Amicus Therapeutics, Inc., with the transaction expected to close on April 27, 2026.

BioMarin Pharmaceutical Inc. announced the discontinuation of certain Phase 2 trials for VOXZOGO due to safety concerns observed in external studies.

BioMarin Pharmaceutical Inc. reported its first quarter 2026 financial results, highlighting increased revenues driven by key products, while also detailing significant progress and financing related to its acquisition of Amicus Therapeutics.

BioMarin Pharmaceutical Inc. reported a net loss of $30.7 million for the third quarter of 2025, primarily driven by a $221 million acquired in-process R&D expense from the Inozyme Pharma acquisition, despite strong revenue growth from key products.

BioMarin Pharmaceutical Inc. reported a significant increase in net income and revenues for the second quarter and first half of 2025, driven by strong performance across its commercial product portfolio and strategic pipeline advancements.

BioMarin Pharmaceutical Inc. announces positive Q1 2025 financial results, highlighted by a significant increase in net product revenues and net income compared to the same period last year.

BioMarin Pharmaceutical Inc. announced its third quarter 2024 results, highlighting significant revenue growth and strategic restructuring efforts.

BioMarin Pharmaceutical Inc. announced its second quarter 2024 results, highlighting revenue growth driven by VOXZOGO and progress in its research and development pipeline.

BioMarin Pharmaceutical Inc. achieved $3.2 billion in total revenues in 2025, driven by VOXZOGO expansion, while strategically withdrawing ROCTAVIAN from the market and pursuing significant acquisitions to bolster its rare disease portfolio.

BioMarin achieved $2.9 billion in total revenues in 2024, fueled by VOXZOGO's growth and pipeline advancements, while implementing a new corporate strategy focused on innovation, growth, and value commitment.

BioMarin Pharmaceutical Inc. achieved $2.4 billion in total revenues in 2023, driven by VOXZOGO expansion and key pipeline advancements, including FDA approvals for VOXZOGO and ROCTAVIAN.

BioMarin Pharmaceutical Inc. director Athena Countouriotis was granted 7,490 restricted stock units as part of equity compensation.

Director Timothy P. Walbert acquired 7,490 restricted stock units in BioMarin Pharmaceutical Inc. as part of a standard equity grant.

BioMarin Pharmaceutical Inc. director Maykin Ho was granted 7,490 restricted stock units as part of an equity compensation arrangement.

Director Robert J. Hombach was granted 7,490 restricted stock units by BioMarin Pharmaceutical Inc. on June 2, 2026.

Director Mark J. Enyedy was granted 7,490 restricted stock units by BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. director Willard H. Dere was granted 7,490 restricted stock units as part of equity compensation.

BioMarin Pharmaceutical Inc. has released its 2026 proxy statement detailing director elections, executive compensation, and a proposed amendment to its 2017 Equity Incentive Plan.

BioMarin Pharmaceutical Inc. has filed a definitive proxy statement with the SEC.

BioMarin is asking stockholders to approve an amendment to its 2017 Equity Incentive Plan to increase the number of shares reserved for issuance.

BioMarin Pharmaceutical Inc. has filed a definitive proxy statement with the SEC.

BioMarin Pharmaceutical Inc. has announced its Annual Meeting of Stockholders to be held on May 21, 2024, and provided updates on its 2023 financial performance and strategic priorities.

Vanguard Capital Management has reported a beneficial ownership of 5.25% in BioMarin Pharmaceutical Inc. as of March 31, 2026.

BlackRock, Inc. has reported a 9.1% beneficial ownership stake in BioMarin Pharmaceutical Inc., holding 17,560,751 common shares as of December 31, 2025.

Viking Global Investors LP and its affiliates report a passive beneficial ownership of 4.3% in BioMarin Pharmaceutical Inc. common stock.

Viking Global Investors LP and its affiliates, along with key executives, have disclosed a collective beneficial ownership of 6.4% in BioMarin Pharmaceutical Inc., totaling 12,288,611 shares.

PRIMECAP MANAGEMENT CO/CA/ has increased its beneficial ownership in BioMarin Pharmaceutical Inc. to 8.24% of the common stock.

Capital Research Global Investors, a division of Capital Research and Management Company, has filed an amended Schedule 13G disclosing a 4.8% beneficial ownership stake in BioMarin Pharmaceutical Inc. as of March 31, 2025.